HUTCHMED Ltd (HCM) Form 6-K — Oct 29, 2026
HUTCHMED announced that the US FDA has granted Orphan Drug Designation to sovleplenib, a novel oral Syk inhibitor, for the treatment of primary immune thrombocytopenia (ITP), a rare autoimmune bleeding disorder. The designation makes sovleplenib eligible for 7 years of US market exclusivity upon approval, plus tax credits for qualified clinical trials, user fee waivers, and specialized FDA guidance. HUTCHMED retains all worldwide rights to the drug. In China, NDAs for sovleplenib in primary ITP and warm antibody autoimmune hemolytic anemia are already under NMPA review, supported by positive pivotal ESLIM-01 and ESLIM-02 trial data.
Key figures
- Incidence per 100k adults
- 3.3
- Rare disease threshold us
- 200000
- Prevalence per 100k adults
- 9.5
- Market exclusivity years us
- 7
- Estimated itp patients china
- 110000
- Estimated itp patients major markets ex china
- 145000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.